Saghmos Receives Japanese Patent for ST-62516 Cardiorenal Drug

Saghmos Therapeutics, a biopharmaceutical firm, has secured a patent from the Japanese Patent Office for its Phase 3-ready drug, ST-62516, also known as trimetazidine, a cardiorenal metabolic modulator. The patent offers the company exclusive rights until 2037, with a broad scope that includes claims for mitigating acute kidney injury in patients with chronic kidney disease (CKD) who are undergoing procedures involving contrast dyes.

The company's CEO, Anna Kazanchyan, expressed enthusiasm over the expansion of their patent portfolio, which now includes a granted US patent and allowances for a second US patent and the Japanese patent. Saghmos is focused on developing ST-62516 to diminish the risks of acute kidney injury and major adverse cardiac and kidney events following contrast procedures such as percutaneous coronary intervention (PCI). The FDA has already cleared the Investigational New Drug (IND) application for ST-62516 in 2023.

In the United States, over a million PCI procedures are conducted annually, primarily on patients with unstable angina. Approximately half of these patients have other health issues like heart disease, diabetes, or are over the age of 75, factors that can affect the safety of PCI. Several procedure-related elements can also result in acute kidney injury and major adverse cardiac and kidney events, which are significant unmet medical needs. There are currently no FDA-approved drugs to prevent or treat these conditions, making ST-62516 a potential asset for all PCI patients, not just those with other health complications.

Saghmos Therapeutics has been granted a US patent (number 11,123,345) for preventing and treating acute kidney injury following contrast procedures. The company has also recently appointed new leadership, with Fred Hassan becoming Chairman of the Board of Directors and Dr. Stephen Grant taking on the role of Chief Regulatory Officer.